Glial fibrillary acidic protein (GFAP) is an intermediate filament (IF) III protein uniquely found in astrocytes in the central nervous system (CNS), non-myelinating Schwann cells in the peripheral nervous system (PNS), and enteric glial cells. GFAP mRNA expression is regulated by several nuclear-receptor hormones, growth factors, and lipopolysaccharides (LPSs). GFAP is also subject to numerous post-translational modifications (PTMs), while GFAP mutations result in protein deposits known as Rosenthal fibers in Alexander disease. GFAP gene activation and protein induction appear to play a critical role in astroglial cell activation (astrogliosis) following CNS injuries and neurodegeneration. Emerging evidence also suggests that, following traumatic brain and spinal cord injuries and stroke, GFAP and its breakdown products are rapidly released into biofluids, making them strong candidate biomarkers for such neurological disorders.
GFAP overview and outline
Astrocytes are a type of glial cell in the CNS, a group that also includes resident and perivascular microglia, oligodendrocytes, radial glia, and Mü ller cells. It is estimated that astroglial cells are the most abundant cell types in the brain, providing both structural and functional support for neurons (including neurotransmitter glutamate recycling and trophic factor release). Astrocytes (astroglia) are characterized by the presence of a unique structural protein, GFAP, isolated and characterized by Dr Eng in 1969 [1] . GFAP is known to be present in non-myelinating Schwann cells in the PNS and enteric glial cells as part of the enteric nervous system (ENS) [2, 3] . In this review, we first examine the structural layout of GFAP, its various splice variants, and the pathological significance of GFAP mutations. We discuss how GFAP is regulated both at the transcriptional and the post-translational levels and how such regulations might impact on GFAP's normal cytoskeletal functions and its involvement in maintaining the activated astroglial cell state (astrogliosis) following nervous system injury. We further focus on the emerging evidence for GFAP and its modified forms as a promising protein biomarker for neurotrauma and stroke. Lastly, we also discuss how GFAP was identified as a dominant autoantigen following traumatic brain injury (TBI) and its implications in terms of triggering a possible post-TBI and sustained autoimmune response toward the nervous system. (Figure 1) [Su, A., ed. (2012) Dataset: GeneAtlas U133A, gcrma (http://biogps.org/ dataset/1/)] [4], almost exclusively in astrocytes. GFAP is also present in the PNS along peripheral nerve fiber tracks, such as the sciatic nerve. In this case, GFAP is localized to non-myelinating Schwann cells that are believed to be functionally similar to astrocytes [5, 6] . In addition, GFAP can be found in the glial cells of the ENS [2, 3] . Such subepithelial glial cells have a trophic and supporting function of the intestinal epithelial cells and neurons. In addition, as GFAP-bearing glial cells are immediately associated with the enteric neurons and their nerve fibers in the submucosal and muscle layers of the gut, they are perfectly positioned to exert a neuromodulation function [for example, by active uptake of extracellular neurotransmitters by glial cell surface neurotransmitter (NT) transporters and subsequent degradation]. The enteric glial cell surface also has receptors for various NTs including purine P1 and P2 receptors that are responsive to neuron-released nucleotides and adenosine [7] . Since enteric neurons regulate gut motility and mucosal secretion, GFAP-bearing glial cells are thought to indirectly influence such processes as well. GFAP levels in enteric glial cells are also responsive to proinflammatory signals such as interleukin-6 (IL-6) or bacterial endotoxin LPS [8] . Similarly, GFAP and glial derived neurotrophic factor (GDNF) levels are highly upregulated in the mucosal plexus in the colon of patients with inflammatory bowel disease (IBD) [9] . In particular, GFAP might be an excellent index of the enteric gliosis response to the more severe forms of IBD (such as ulcerative and infectious colitis) over Crohn's disease. Intriguingly, mouse enteric glia can undergo neurogenesis in response to injury [3] . In addition, enteric GFAP levels and phosphorylation are also increased in Parkinson's disease (PD) patients [10] . Further investigation is needed to understand the possible implications of this finding in PD patients. 
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